Gapping up
In reaction to strong earnings/guidance:
- AMKR +18.2%, VRNS +14.8%, TXRH +13.6%, HLIT +8.8%, SHOO +8.8%, LODE +6.2%, NXPI +4.9%, FMS +4.9%, INCY +4.5%, GRFS +4%, MLM +3.7%, PAG +3.7%, NMR +3.4%, EXLS +3.3%, CEQP +3.3%, TRTX +2.9%, I +2.9%, PFE +2.9%, MRK +2.7%, VSH +2.7%, OMF +2.6%, XRX +2.6%, AUDC +2.3%, AN +2.3%, APPF +2.1%, NEO +2.1%, PCH +1.8%, GLW +1.8%, LDOS +1.6%, IR +1.6%, NXRT +1.6%, RE +1.2%, RGS +1.2%, WH +1.2%, MMC +1.2%, ZBRA +1%, COP +0.8%, TBI +0.7%, AKAM +0.7%, FDP +0.7%
Other news:
- MRTX +12% (announces first clinical results from Phase 1/2 trial evaluating MRTX849 in patients with solid tumors expressing KRAS G12C mutations)
- FG +10.7% (to join S&P SmallCap 600)
- TALO +6.7% (to join S&P SmallCap 600)
- S +2.1% (ahead of earnings on Oct 30 before the open; also following TMUS results)
- NXRT +1.6% (increases quarterly dividend to $0.3125 per share from $0.275 per share)
Analyst comments:
- DCPH +2.4% (upgraded to Mkt Perform from Underperform at SVB Leerink)
- DRNA +1.7% (initiated with Outperform at Robert W. Baird)
- UPS +0.9% (initiated with an Outperform at Wells Fargo)
